Oragenics Selects Southern Star Research As Clinical Research Organization for ONP-002 Phase IIa Trial
UF Innovate | Accelerate graduate Oragenics, Inc., announced the selection of Southern Star Research as its Clinical Research Organization (CRO) for the upcoming Phase IIa clinical trial of ONP-002, the company’s lead drug candidate for concussion.
Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement To Support ONP-002 Clinical Development
UF Innovate | Accelerate graduate Oragenics, Inc., has announced a manufacturing agreement with Sterling Pharma Solutions, a leading U.S.-based CDMO with multiple development and production facilities.
Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial
UF Innovate | Accelerate graduate Oragenics announced that it has submitted a clinical trial protocol for regulatory review to the Health and Disability Ethics Committee (HDEC) in New Zealand.
Oragenics, Inc. Submits Investigator’s Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury
UF Innovate | Accelerate graduate Oragenics, Inc. announced the submission of its Investigator’s Brochure (IB) application in preparation for its Phase II clinical trial using ONP-002 in Australia.
Oragenics Develops Automated Intranasal Device for Treating Concussed Patients
Oragenics, Inc., a UF Innovate | Accelerate alumnus company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, announced it has completed a prototype of its automated intranasal device for use in concussed patients who are initially confused, dazed or unconscious in the acute phase of injury.